Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This article reviews the use of dermoscopy in distinguishing temporal triangular alopecia from alopecia areata, emphasizing its role in avoiding invasive diagnostics and ineffective treatments; it reports no new clinical findings.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This study found that adenosine significantly increased the proportion of thick hair in Caucasian men with androgenetic alopecia, with no reported adverse effects.

Targeted testing for telogen effluvium patients can save healthcare costs.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This article includes visual documentation of eyebrow morphology during a disease course, but reports no new research findings.

In this study, tibial cortex transverse transport accelerated wound healing in diabetic rats, potentially through enhanced mobilization of non-classical monocytes and increased M2 macrophage polarization.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.

This study found that using histidine-tryptophan-ketoglutarate solution with adenosine triphosphate and deferoxamine for hair graft preservation significantly reduced postsurgical shedding compared to Ringer solution, enhancing patient satisfaction.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

This study demonstrated that switching aE-catenin to aT-catenin in murine skin substantially rescued hyperproliferative and pre-cancerous conditions, but led to partial baldness, indicating potential functional discrepancies.

In this study, tofacitinib treatment in a male patient with alopecia areata led to significant hair regrowth and improvement in nail dystrophy symptoms, restoring finger function within 10 months.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study found that specific ATP-competitive TOR inhibitors (asTORis) decrease root growth in Arabidopsis thaliana in a dose-dependent manner, similar to their effects on mammalian cells.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

This research developed a mouse model for alopecia areata by transferring lymph node cells from affected mice and reported that treatments with Ritlecitinib or Tacrolimus significantly improved symptoms, with Tacrolimus achieving near-complete hair regrowth.